Selected publications
-
A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC.
EJNMMI Research.
2017
Academic Article
GET IT
Times cited: 7 -
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Clinical Lung Cancer.
2017
Academic Article
GET IT
Times cited: 12 -
Phase I dose-escalation study of linsitinib (OSI-906) and erlotinib in patients with advanced solid tumors.
Clinical Cancer Research.
2016
Academic Article
GET IT
Times cited: 16 -
Alterations of immune response of non-small cell lung cancer with Azacytidine.
Oncotarget.
2013
Academic Article
GET IT
Times cited: 207 -
Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.
Journal of Thoracic Oncology.
2013
Academic Article
GET IT
Times cited: 75 -
Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic target.
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting.
2013
Review
GET IT
Times cited: 9 -
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Cancer Discovery.
2011
Academic Article
GET IT
Times cited: 389